Recent Faculty Research Awards and Grants
James DiRenzo, Ph.D., Associate Professor of Pharmacology and Toxicology, has been awarded a two year grant from the Department of Defense (6/15/2010-6/14/2012) entitled: Targeting Breast Cancer Recurrence via Hedgehog-mediated Sensitization of Breast Cancer Stem Cells.
Dr. DiRenzo has been awarded a one year grant from the Elsa Pardee Foundation (1/01/2010-12/31/2010), entitled: Targeting Cancer Recurrence via Disruption of Tumor Stem Cell Quiescence.
Ethan Dmitrovsky, M.D., Professor of Pharmacology and Toxicology and of Medicine, and Yolanda Sanchez, PhD, Associate Professor of Pharmacology and Toxicology, have been awarded a one year Samuel Waxman Cancer Research Foundation grant (7/1/10-6/30/11), entitled: Rexinoid Therapy for Lung Cancer Prevention.
Michael Spinella, Ph.D., Associate Professor of Pharmacology and Toxicology, has been awarded a three year Department of Defense award (6/01/2010-5/31/2013), entitled: Molecular Mechanisms of DNA Methylation Inhibition Therapy for Testicular Cancer in Adolescents.
Michael Sporn, M.D., Oscar M. Cohn '34 Professor of Pharmacology and Toxicology and of Medicine, has renewed a one year contract with REATA Pharmaceuticals (8/01/2012-7/31/2013), entitled: Sponsored Research Agreement on Triterpenoids.
Reata Pharmaceuticals, Inc. and Kyowa Hakko Kirin Co., Ltd. Have announced that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata's lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets. Under the terms of the agreement, Reata is eligible to receive up to $272 million in up-front fees and milestone payments, in addition to double-digit royalties. The drug belongs to a family of anti-inflammatory compounds called triterpenoids, which chemist Tadashi Honda, PhD, began synthesizing at the Dartmouth laboratory of Gordon Gribble, PhD, in 1995. Since then, Cancer Center Cancer Epidemiology and Chemoprevention Research Program member Michael Sporn, MD, co-investigator Karen Liby, PhD, and his lab team have been testing them for bioactivity.
September 23, 2010, Abbott and Reata Pharmaceuticals announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 3 trials for the treatment of chronic kidney disease (CKD). Under terms of the agreement, Reata will grant to Abbott exclusive rights to develop and commercialize bardoxolone outside the U.S., excluding certain Asian markets.
(information taken from Reata Pharmaceuticals and Norris Cotton Cancer Center websites)